Momenta Pharmaceuticals News Releases http://ir.momentapharma.com/ Momenta Pharmaceuticals News Releases en Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-webcast-presentation-goldman-sachs-40th CAMBRIDGE, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler , President and CEO, will present Tue, 04 Jun 2019 07:30:00 -0400 Momenta Pharmaceuticals News Releases 20236 Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-webcast-presentation-2019-bank-america CAMBRIDGE, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler , President and CEO, will present at Thu, 09 May 2019 08:00:00 -0400 Momenta Pharmaceuticals News Releases 20151 Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-reports-first-quarter-2019-financial-and — M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG transfer in perfusion model of the human term placenta, published in American Journal of Obstetrics & Gynecology — — First Thu, 02 May 2019 07:00:00 -0400 Momenta Pharmaceuticals News Releases 20136 Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-date-first-quarter-2019 CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the Thu, 18 Apr 2019 08:00:00 -0400 Momenta Pharmaceuticals News Releases 20071 Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019 http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-presentations-american - Data highlight potential of Fc multimerization technology platform to significantly enhance the potency and efficacy of therapeutic antibodies - CAMBRIDGE, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and Thu, 28 Mar 2019 07:00:00 -0400 Momenta Pharmaceuticals News Releases 19991 Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-publication-new-data Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and newborn    Global multi-center Phase 2 study of M281 in hemolytic disease of the fetus and newborn (HDFN) now active following Thu, 21 Mar 2019 08:43:00 -0400 Momenta Pharmaceuticals News Releases 19986 Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-reports-fourth-quarter-and-full-year -- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 trial of M254 in immune thrombocytopenia (ITP) -- CAMBRIDGE, Mass. , Feb. Fri, 22 Feb 2019 06:30:00 -0500 Momenta Pharmaceuticals News Releases 19931 Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-date-fourth-quarter-and-year-5 CAMBRIDGE, Mass. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the Fri, 08 Feb 2019 08:00:00 -0500 Momenta Pharmaceuticals News Releases 19741 Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-oral-presentation-new-data Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion model M281 currently being evaluated in an international Phase 2 study in Hemolytic Disease of the Fetus and Newborn (HDFN) CAMBRIDGE, Mass. , Feb. Thu, 07 Feb 2019 08:00:00 -0500 Momenta Pharmaceuticals News Releases 19731 Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G http://ir.momentapharma.com/news-releases/news-release-details/momenta-pharmaceuticals-announces-first-subject-dosed-phase-12 CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the dosing of the first subject in the Phase 1/2 Tue, 29 Jan 2019 08:00:00 -0500 Momenta Pharmaceuticals News Releases 19711